Based on an interview about cost effectiveness research with Professor Weinstein https://www.hsph.harvard.edu/news/magazine/winter10assessment/

1. Why are some expensive treatments (like lung transplants and pap smears) considered to be bad value and other expensive treatments (like aromatese inhibitors, an expensive class of drugs to treat breast cancer) to be good value?
2. What can the U.S. do to address the problem of overusing medical care that is not cost effective, and why isn't the U.S. doing this already?

Initial/Original Post